STEMI

BRIGHT-4 Trial Summary: Bivalirudin in STEMI

2022 BRIGHT-4 TRIAL Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with STEMI undergoing primary PCI investigator-initiated, open-label, randomized controlled trial Objective: To evaluate the safety and efficacy of a high-dose infusion of bivalirudin after primary percutaneous coronary … Read More